Real-world evidence of systemic treatment practices for biliary tract cancer in Japan: Results of a database study.
J Hepatobiliary Pancreat Sci
; 31(7): 468-480, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38953871
ABSTRACT
PURPOSE:
To describe the real-world treatment patterns of systemic therapies for biliary tract cancer (BTC) and to examine the frequency and management of biliary infection in Japan.METHODS:
Patients diagnosed with BTC and prescribed systemic therapy between January 2011 and September 2020 were retrieved from the Japanese Medical Data Vision database. The look-back period was set to 5 years. Patient characteristics, treatment patterns, and biliary infection-induced treatment interruption were analyzed.RESULTS:
The full analysis set comprised 22 742 patients with a mean age of 71.0 years and 61.6% were male. The most common BTC type was extrahepatic cholangiocarcinoma (44.6%). The three most common first-line regimens were S-1 monotherapy (33.0%), gemcitabine+cisplatin (32.5%), and gemcitabine monotherapy (18.7%) over the entire observation period (January 2011-September 2021). Patients who received monotherapies tended to be older. Biliary infection-induced treatment interruption occurred in 29.5% of patients, with a median time to onset of 64.0 (interquartile range 29.0-145.0) days. The median duration of intravenous antibiotics was 12.0 (interquartile range 4.0-92.0) days.CONCLUSIONS:
These results demonstrated potential challenges of BTC in Japanese clinical practice particularly use of multiple regimens, commonly monotherapies, which are not recommended as first-line treatment, and the management of biliary infections during systemic therapy.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biliary Tract Neoplasms
/
Databases, Factual
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Asia
Language:
En
Journal:
J Hepatobiliary Pancreat Sci
Year:
2024
Document type:
Article
Affiliation country: